Metoprolol alpha-hydroxylation is a poor probe for debrizoquine oxidation (CYP2D6) polymorphism in Jordanians.
The frequency distribution of the 8-h urinary ratio of log metoprolol/alpha-hydroxymetoprolol was assessed in 65 healthy, unrelated Jordanian volunteers. There was no apparent bimodality in the frequency distribution of this ratio among the subjects studied. The frequency of the poor metabolizer phenotype of metoprolol alpha-hydroxylation was 1.5% (one subject). There was a significant correlation (r = 0.61, P < 0.05, n = 39) between the log metoprolol/alpha-hydroxymetoprolol and the log debrisoquine/4-hydroxydebrisoquine ratios. However, the frequency of poor metabolizer status of debrisoquine among the 39 subjects was 7.7% (three subjects). Only one of the poor metabolizer of metoprolol alpha-hydroxylation. These findings indicate that metoprolol alpha-hydroxylation by CYP2D6 represents a poor probe for studying debrisoquine polymorphism in Jordanians.
al-Hadidi
H F
HF
Department of Pharmacology, Faculty of Medicine, Jordan University of Science and Technology, Irbid.
Irshaid
Y M
YM
Rawashdeh
N M
NM
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D003647:Debrisoquin / Q000378:metabolism*; D006801:Humans; D006900:Hydroxylation; D007597:Jordan; D008297:Male; D008790:Metoprolol / Q000378:metabolism*; D010641:Phenotype; D011110:Polymorphism, Genetic / Q000235:genetics*
D008790:Metoprolol; D003647:Debrisoquin